All News
Filter News
Found 10,128 articles
-
bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
1/13/2020
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany
-
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
1/12/2020
Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL
-
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
1/10/2020
Indapta Therapeutics, Inc., a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic G-NK (FcRγ-deficient Natural Killer) cell therapy to treat multiple cancers, and Lonza today announced a strategic partnership
-
New Report Demonstrates Potential for Cell and Gene Therapies to Provide Cost Savings
1/10/2020
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today announced the release of a report, “A Transformative Therapy Value Model for Rare Blood Diseases.”
-
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
1/10/2020
Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials.
-
International Myeloma Foundation Partners with Medscape Oncology to Create Professional Education Series on Continuous Treatment in Multiple Myeloma
1/9/2020
The International Myeloma Foundation announces the launch of a new program created in partnership with Medscape Oncology that offers healthcare professionals an opportunity to earn continuing medical education (CME) credit
-
NexImmune Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
1/9/2020
NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation nanotechnology platform, announced that industry veterans Han Myint, MD, and John Trainer, MBA, have been appointed as the Company’s Chief Medical Officer and Chief Financial Officer, respectively.
-
New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
1/9/2020
Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes
-
Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference
1/9/2020
Sutro Biopharma, Inc. announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 16, 2020, at 9:00 AM PST at the Westin St. Francis in San Francisco.
-
Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
1/9/2020
Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that ROTH Capital Partners will conduct a Key Opinion Leader call for their institutional clients.
-
Under the collaboration deal with Acerta, Veracyte will offer genomic information in support of Acerta’s oncology development program. Financial details were not disclosed.
-
Sutro Biopharma Appoints James Panek to Board of Directors
1/8/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointment of James P. Panek to its Board of Directors
-
Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.
-
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
1/8/2020
Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial
-
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
1/8/2020
The Antengene board announced the appointment of Mr. Mark J. Alles as an independent director of the company, effective January 2, 2020. Mr. Alles is the former Chairman and Chief Executive Officer of Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company.
-
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia
1/8/2020
Adaptive Biotechnologies Corporation announced that Palmetto GBA, a Medicare Administrative Contractor that assesses diagnostic technologies through its MolDX program, has expanded coverage of the clonoSEQ Assay to include monitoring minimal residual disease in Medicare patients with chronic lymphocytic leukemia.
-
FDA Approves Merck’s KEYTRUDA® for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy
1/8/2020
KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Certain Patients With High-Risk, Non-Muscle Invasive Bladder Cancer
-
Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy
1/8/2020
Preclinical results published in Science Translational Medicine show that adding CD28 costimulatory bispecifics to CD3 bispecifics led to synergistic anti-tumor activity without inducing cytokine storm
-
Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas
1/8/2020
Findings may create immunotherapy options for lymphomas caused by CREBBP mutations
-
Molecular Templates Provides Corporate Update and Outlines 2020 Milestones
1/8/2020
Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships